“May you live in interesting times.”
Viralgen Chief Commercial Officer Andy Holt invokes that apocryphal “half-blessing, half-curse” as he opens his recent appearance on Outsourced Pharma Capacity Update. Andy identifies some of the key dynamics shaping today’s gene therapy manufacturing environment, and then provides an update on how Viralgen is helping innovators of all shapes and sizes meet evolving demands through:
- Integration of inhouse, plug-n-play helper plasmid DNA
- Development services centered on platform fit and construct optimization
- Per-patient pricing COGS modeling to meet large manufacturing needs
Andy also covers Viralgen’s efforts to break early developers’ paradoxical (and painful) cycle: They can’t get data because they don’t have funding, and they can’t get funding because they don’t have data. He describes how the company’s new 2L Launchpad program is designed to be a no-cost/low-cost opportunity for developers to get access to small-scale material and data that provides an early view on clinical entry and COGS.
Get all of Andy’s insights in the video below.
